{"url_path":"/sec/aeon/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000042-index.html","accession_number":"0001837607-26-000042","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000042-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":123,"has_tables":true,"body_markdown":"**Item 1. Legal Proceedings**\n\nOn November 20, 2025, Aegis Capital Corp. (“Aegis”) filed a lawsuit against the Company in the Supreme Court of the State of New York, alleging that the Company failed to honor Aegis’s right of first refusal (the “ROFR”) when AEON raised capital through a self-directed private placement in public equity (“PIPE”). In the complaint, Aegis claimed that AEON misappropriated $1.59 million by not engaging Aegis as its underwriter or bookrunner in the PIPE and sought punitive damages and attorneys' fees. Aegis was unsuccessful in its attempts to obtain both a temporary restraining order and permanent injunction. In April 2026, AEON's motion to dismiss was granted with prejudice, which dismissal Aegis could choose to appeal.\n\n41\n\n[Table of Contents](#TOC)\n\n​"}